Nexalin Technology (NXL) Return on Assets Growth (3y) (2025 - 2026)
Nexalin Technology (NXL) Return on Assets Growth (3y) (2025 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.27 Bn | 175.98 Bn | 6.27 Bn |
| 2 | Stryker | 128.81 Bn | 125.93 Bn | 3.81 Bn |
| 3 | Medtronic | 108.63 Bn | 99.41 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.42 Bn | 66.96 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.51 Bn | 44.84 Bn | 1.29 Bn |
| 6 | Dexcom | 28.39 Bn | 27.27 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.31 Bn | 26.03 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.93 Bn | 26.35 Bn | - |
| 9 | Koninklijke Philips | 25.47 Bn | 22.35 Bn | 2.07 Bn |
| 10 | Nexalin Technology | 9.43 Mn | 6.72 Mn | 13,133.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.00 |
| Dec 31, 2025 | -1.00 |